← Eichor
Study identifier: NCT06357533 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Condition: Non-Small Cell Lung Cancer  ·  Sponsor: AstraZeneca

PhasePhase 3
Planned participants675
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center  ·  1-877-240-9479  ·  information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (286)

Research SiteAnchorage, Alaska, United StatesRecruiting
Research SiteTucson, Arizona, United StatesRecruiting
Research SiteLittle Rock, Arkansas, United StatesRecruiting
Research SiteSpringdale, Arkansas, United StatesRecruiting
Research SiteAnaheim, California, United StatesRecruiting
Research SiteBeverly Hills, California, United StatesRecruiting
Research SiteFountain Valley, California, United StatesRecruiting
Research SiteNewport Beach, California, United StatesSuspended
Research SiteClermont, Florida, United StatesRecruiting
Research SiteGainesville, Florida, United StatesRecruiting
Research SiteMiami Beach, Florida, United StatesRecruiting
Research SiteOrange City, Florida, United StatesRecruiting

+ 274 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06357533